Value Investors: 1 Pharma Growth Stock With Huge Potential

Aurinia Pharmaceuticals Inc. (TSX:AUP)(NASDAQ:AUPH) has an extensive granted patent portfolio which makes the company’s stock very valuable.

| More on:
pharma, vaccine, coronavirus, COVID

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Aurinia Pharmaceuticals (TSX:AUP)(NASDAQ:AUPH) is a biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company has commercially launched voclosporin in the United States (U.S.) for the treatment of adult patients with active Lupus nephritis (LN). It continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program.

Robust business strategy

The company’s business strategy is to optimize the clinical and commercial value of voclosporin and become a commercial biopharmaceutical company with a global product portfolio focused on less common kidney and autoimmune diseases with high unmet medical needs. This includes the potential expansion of the existing label for additional kidney indications, the evaluation of voclosporin in novel formulations for the treatment of other autoimmune related disorders, as well as the addition of new pipeline assets that align with the company’s core expertise.

The company has developed a strategic plan to execute on Aurinia’s commercialization of voclosporin as a treatment of adult patients with active LN and to expand the company’s franchise beyond LN. The company plans on obtaining FDA approval for use of voclosporin for the treatment of active LN.

Strategic supply arrangements

Further, the company is conducting post-commercial activities including build out of the organization to efficiently and effectively market voclosporin as a treatment of adult patients with active LN. It has engaged Otsuka as a collaboration partner for development and commercialization of voclosporin in Europe. The company also plans to seek approval with the European Medicines Agency in the first half of 2021, and other territories including the United Kingdom (U.K.), Switzerland, Russia, and Japan.

Aurinia is also working on ensuring adequate supply of voclosporin becomes available and the company has entered into strategic long term supply agreements with several key suppliers. The company is evaluating external assets with the potential to be synergistic and complementary to Aurinia’s clinical, regulatory and therapeutic areas of expertise.

Significant market potential

The company has conducted extensive market research and analyses of peer reviewed publications to assess market potential and commercial opportunity. Aurinia’s physician research included more than 1,100 rheumatologists and nephrologists across the U.S., Europe and Japan to assess the potential market for adoption of voclosporin and estimate pricing and treatment possibilities.

The National Institute of Diabetes and Digestive and Kidney Diseases estimates that up to 50% of adults with systemic lupus erythematosus (SLE) are diagnosed with lupus nephritis at some point of the patient’s journey with lupus. Using the research and publication analyses, the company estimates the number of SLE patients diagnosed with LN to be about 80,000 to 120,000 in the U.S. This creates incredible opportunity for the company.

Valuable patent portfolio

Aurinia’s policy has been to file patent applications to protect technology, inventions and improvements to the company’s inventions that are considered important to the development of Aurinia’s business. The company has an extensive granted patent portfolio which makes Aurinia’s stock very valuable. Aurinia’s intrinsic value appears to far exceed the stock’s market price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Investing

Workers use a microscope to do medical research in a modern laboratory.

Is Now the Time to Buy Health Care Stocks?

Health care stocks are on the up, but does that mean you should go ahead and buy anything? In short:…

Read more »

Volatile market, stock volatility

2 Volatile Stocks to Hold for a Decade

The market is full of opportunities for investors. But does that opportunity include some volatile stocks to hold?

Read more »

Arrowings ascending on a chalkboard

1 Under-the-Radar U.S. Stock to Buy in August

Canadians on the hunt for an undervalued and under-the-radar U.S. stock should consider Match Group Inc.

Read more »

Woman has an idea
Dividend Stocks

2 Low-Risk Growth Stocks Paying Great Dividends

These top TSX dividend stocks give investors exposure to interesting growth opportunities.

Read more »

A person builds a rock tower on a beach.
Dividend Stocks

Got $300? 2 Simple TSX Stocks to Buy Right Now

These two simple TSX stocks have everything a long-term investor looking to dollar cost average into a position wants right…

Read more »

A golden egg in a nest
Dividend Stocks

Millennials: No Excuses! Start Saving for Retirement Right Now.

Millennials, we need to stop complaining and start bragging. We're great savers, so it's time to start investing in TSX…

Read more »

Value for money
Dividend Stocks

3 UNDERVALUED TSX Stocks to Buy in August

Here are some attractively valued TSX stocks for the long term.

Read more »

A young man throwing and catching his daughter above his head
Dividend Stocks

Parents: Double Your CCB Payments This Month!

Parents can use those CCB payments to their benefit and double them this year month after month -- no waiting,…

Read more »